Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
deals
6
×
genentech
6
×
life sciences
national blog main
national top stories
san francisco blog main
new york blog main
san francisco top stories
cancer
eli lilly
fda
new york top stories
san diego blog main
san diego top stories
startups
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
ipo
national
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
agenus
boston
What
bio
drug
roundup
big
cancer
companies
fda
liver
medicines
pharmaceutical
roche
acquire
agreed
aiming
alzheimer’s
ambys
appetite
approval
approved
billion
biotech
black
blueprint
bread
broad
butter
buyout
candidate
cash
confidence
control
currently
deadly
deal
debuted
diabetes
diamond’s
didn’t
different
digital
Language
unset
Current search:
genentech
×
deals
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine